Chemours
Market Cap
US$2.5b
Last Updated
2019/12/07 00:49 UTC
Data Sources
Company Financials +
Executive Summary
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America.
Rewards
Risk Analysis
Snowflake Analysis
Undervalued average dividend payer.
Similar Companies
Share Price & News
How has Chemours's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CC has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
5.6%
CC
-0.5%
US Chemicals
-0.3%
US Market
1 Year Return
-36.1%
CC
1.7%
US Chemicals
18.6%
US Market
Return vs Industry: CC underperformed the US Chemicals industry which returned -1% over the past year.
Return vs Market: CC underperformed the US Market which returned 15.5% over the past year.
Shareholder returns
| CC | Industry | Market | |
|---|---|---|---|
| 7 Day | 5.6% | -0.5% | -0.3% |
| 30 Day | -15.1% | -1.6% | 2.2% |
| 90 Day | 13.8% | 4.9% | 5.6% |
| 1 Year | -32.8%-36.1% | 17.4%1.7% | 21.1%18.6% |
| 3 Year | -31.5%-36.4% | 32.6%7.6% | 45.6%36.2% |
| 5 Year | n/a | 53.3%20.4% | 71.1%52.2% |
Price Volatility Vs. Market
How volatile is Chemours's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is The Chemours Company (NYSE:CC) A Smart Pick For Income Investors?2 weeks ago | Simply Wall St
Should You Worry About The Chemours Company's (NYSE:CC) CEO Pay?4 weeks ago | Simply Wall St
The Chemours Company Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowValuation
Is Chemours undervalued compared to its fair value and its price relative to the market?
34.3%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CC ($16.68) is trading below our estimate of fair value ($25.38)
Significantly Below Fair Value: CC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CC is good value based on its PE Ratio (6.8x) compared to the Chemicals industry average (20.2x).
PE vs Market: CC is good value based on its PE Ratio (6.8x) compared to the US market (18.3x).
Price to Earnings Growth Ratio
PEG Ratio: CC is good value based on its PEG Ratio (0.4x)
Price to Book Ratio
PB vs Industry: CC is overvalued based on its PB Ratio (3.3x) compared to the US Chemicals industry average (2.2x).
Next Steps
Future Growth
How is Chemours forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
16.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CC's forecast earnings growth (16.4% per year) is above the savings rate (1.7%).
Earnings vs Market: CC's earnings (16.4% per year) are forecast to grow faster than the US market (14.2% per year).
High Growth Earnings: CC's earnings are forecast to grow, but not significantly.
Revenue vs Market: CC's revenue (4.8% per year) is forecast to grow slower than the US market (7.4% per year).
High Growth Revenue: CC's revenue (4.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CC's Return on Equity is forecast to be very high in 3 years time (61.7%).
Next Steps
Past Performance
How has Chemours performed over the past 5 years?
35.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CC has high quality earnings.
Growing Profit Margin: CC's current net profit margins (7.2%) are lower than last year (16%).
Past Earnings Growth Analysis
Earnings Trend: CC's earnings have grown significantly by 35% per year over the past 5 years.
Accelerating Growth: CC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CC had negative earnings growth (-62.4%) over the past year, making it difficult to compare to the Chemicals industry average (-17%).
Return on Equity
High ROE: Whilst CC's Return on Equity (48.28%) is outstanding, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Chemours's financial position?
Financial Position Analysis
Short Term Liabilities: CC's short term assets ($2.8B) exceed its short term liabilities ($1.6B).
Long Term Liabilities: CC's short term assets ($2.8B) do not cover its long term liabilities ($5.0B).
Debt to Equity History and Analysis
Debt Level: CC's debt to equity ratio (486%) is considered high.
Reducing Debt: Insufficient data to determine if CC's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: CC's debt is not well covered by operating cash flow (12.4%).
Interest Coverage: CC's interest payments on its debt are well covered by EBIT (3x coverage).
Balance Sheet
Inventory Level: CC has a high level of physical assets or inventory.
Debt Coverage by Assets: CC's debt is not covered by short term assets (assets are 0.7x debt).
Next Steps
Dividend
What is Chemours's current dividend yield, its reliability and sustainability?
6.00%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: CC's dividend (6%) is higher than the bottom 25% of dividend payers in the US market (1.43%).
High Dividend: CC's dividend (6%) is in the top 25% of dividend payers in the US market (3.71%)
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, CC has been paying a dividend for less than 10 years.
Growing Dividend: CC's dividend payments have increased, but the company has only paid a dividend for 4 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (41%), CC's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: CC's dividends in 3 years are forecast to be well covered by earnings (25.7% payout ratio).
Next Steps
Management
What is the CEO of Chemours's salary, the management and board of directors tenure and is there insider trading?
1.7yrs
Average management tenure
CEO
Mark Vergnano (61yo)
4.4yrs
Tenure
US$8,076,729
Compensation
Mr. Mark P. Vergnano has been the Chief Executive Officer and President at The Chemours Company since July 01, 2015. Mr. Vergnano served as the Chief Executive Officer of Performance Chemicals at E. I. du ...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD8.08M) is above average for companies of similar size in the US market ($USD5.10M).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
Management Age and Tenure
1.7yrs
Average Tenure
55.5yo
Average Age
Experienced Management: CC's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Age and Tenure
4.4yrs
Average Tenure
62yo
Average Age
Experienced Board: CC's board of directors are considered experienced (4.4 years average tenure).
Insider Trading
Insider Buying: CC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Operating Officer Senior VP & COO |
| Shares | 20,000 |
| Max Price | US$16.42 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 1,790 |
| Max Price | US$13.99 |
| Entity | Individual |
| Role | Chief Legal Officer Senior VP |
| Shares | 15,000 |
| Max Price | US$13.82 |
| Entity | Individual |
| Role | Senior Key Executive President of Titanium Technologies |
| Shares | 12,000 |
| Max Price | US$13.77 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 5,000 |
| Max Price | US$14.67 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 3,500 |
| Max Price | US$14.15 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 44,000 |
| Max Price | US$23.17 |
| Entity | Individual |
| Role | Head of Human Resources Senior Vice President of Human Resources & Health Services |
| Shares | 6,500 |
| Max Price | US$23.06 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 1,044 |
| Max Price | US$23.91 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 5,000 |
| Max Price | US$24.06 |
| Entity | Individual |
| Shares | 1,080 |
| Max Price | US$39.10 |
| Entity | Individual |
| Role | Chief Operating Officer Senior VP & COO |
| Shares | 59,210 |
| Max Price | US$38.26 |
| Entity | Individual |
| Shares | 10,000 |
| Max Price | US$38.66 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Mark Vergnano (61yo)
President
- Tenure: 4.4yrs
- Compensation: US$8.08m
Mark Newman (56yo)
Senior VP & COO
- Tenure: 0.5yrs
- Compensation: US$2.30m
Susan Kelliher (52yo)
Senior Vice President of Human Resources & Health Services
- Tenure: 0yrs
Sameer Ralhan
Senior VP
- Tenure: 0.5yrs
E. Snell (62yo)
President of Titanium Technologies
- Tenure: 4.6yrs
- Compensation: US$1.68m
Erich Parker (68yo)
Senior VP of Corporate Communications & Chief Brand Officer
- Tenure: 4.8yrs
Dave Shelton (55yo)
Senior VP
- Tenure: 5.1yrs
- Compensation: US$1.75m
Ed Sparks (45yo)
President of Chemical Solutions & Fluoroproducts
- Tenure: 1.7yrs
Jonathan Lock
Vice President of Corporate Development & Investor Relations
- Tenure: 1.6yrs
Matthew Abbott (43yo)
VP, Chief Accounting Officer & Controller
- Tenure: 0.3yrs
Board Members
Brad Bell (66yo)
Independent Director
- Tenure: 4.4yrs
- Compensation: US$250.05k
Dick Brown (71yo)
Independent Chairman of the Board
- Tenure: 4.4yrs
- Compensation: US$340.05k
Curt Crawford (71yo)
Independent Director
- Tenure: 4.4yrs
- Compensation: US$245.05k
Mary Cranston (71yo)
Independent Director
- Tenure: 4.4yrs
- Compensation: US$237.55k
Curt Anastasio (62yo)
Independent Director
- Tenure: 4.4yrs
- Compensation: US$230.05k
Dawn Farrell (59yo)
Independent Director
- Tenure: 4.9yrs
- Compensation: US$230.05k
Sean Keohane (52yo)
Independent Director
- Tenure: 1.6yrs
- Compensation: US$205.05k
Mark Vergnano (61yo)
President
- Tenure: 4.4yrs
- Compensation: US$8.08m
Erin Kane (42yo)
Independent Director
- Tenure: 0.5yrs
Company Information
The Chemours Company's company bio, employee growth, exchange listings and data sources
Key Information
- Name: The Chemours Company
- Ticker: CC
- Exchange: NYSE
- Founded: 2014
- Industry: Diversified Chemicals
- Sector: Materials
- Market Cap: US$2.516b
- Shares outstanding: 163.50m
- Website: https://www.chemours.com
Number of Employees
Location
- The Chemours Company
- 1007 Market Street
- Wilmington
- Delaware
- 19899
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CC | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jun 2015 |
| CC * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jun 2015 |
| 2CU | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2015 |
| 0HWG | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jun 2015 |
Biography
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Fluoroproducts, Chemical Solu ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/07 00:49 |
| End of Day Share Price | 2019/12/06 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.